Cellular transport of CI-980

Investigational New Drugs

Volumn 14, Issue 4, 1996, Pages 341-347

  Hook, Kenneth E ^a   Przybranowski, Sally A ^a   Leopold, W R ^a  

^a PFIZER INC   (United States)

Author keywords

CI 980; Mitotic inhibitor; PD 132183

Indexed keywords

FOLIC ACID ANTAGONIST; MIVOBULIN ISETHIONATE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BINDING; DRUG DIFFUSION; DRUG TRANSPORT; DRUG UPTAKE; ENANTIOMER; MEMBRANE TRANSPORT; NONHUMAN; PRIORITY JOURNAL;

EID: 0030470542     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00180809     Document Type: Article

References (25)

1. Temple C Jr, Wheeler GP, Elliott RD, Rose JD, Comber RN: 1,2-dihydropyrido[3,4-b]pyrazines: structure-activity relationships. J Med Chem 26:91-95, 1983
2. Bowdon BJ, Waud WR, Wheeler GP, Hain R, Dansby L, Temple C Jr: Comparison of 1,2-dihydropyrido[3,4-b]pyrazines (1-deaza-7,8-dihydropteridines) with several other inhibitors of mitosis. Cancer Res 47:1621-1626, 1987
3. Wheeler GP, Bowdon BJ, Temple C Jr, Adamson DJ, Webster J: Biological effects and structure-activity relationships of 1,2-dihydropyrido[3,4-b]pyrazines. Cancer Res 43:3567-3575, 1983
4. Griswold DP Jr, Temple CG Jr, Trader MW, Leopold WR III, Laster WR Jr, Dykes DJ: Antitumor activity of a novel 1,2 dihydropyrido[3,4-b]pyrazine in preclinical drug-sensitive and -resistent tumors. Proc Am Assoc Cancer Res 27:306, 1986
5. Waud WR, Leopold WR, Elliott WL, Dykes DJ, Laster WR Jr, Temple CG Jr, Harrison SD Jr, Griswold DP Jr: Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate (NSC 370147) against selected tumor systems in culture and in mice. Cancer Res 50:3239-3244, 1990
6. Leopold WR, Elliott WL, Przybranowski SA, Waud WR: In vivo evaluation of the potential for therapeutic synergy between CI-980 and standard chemotherapeutic agents. Proc Am Assoc Cancer Res 34:296, 1993
7. Noker PE, Hill DL, Kalin JR, Temple CG, Montgomery JA Jr: Pharmacokinetic and metabolism studies of two novel 1-deaza7,8-dihydropteridines in mice. Drug Metabolism and Deposition 13:677, 1985
8. Sklarin NT, Benson L, Roca J, Einzig AI, Wiernik PH, Whitfield LR, Lathia C, Kowal C, Grove W: Phase I study of CI-980: 24-hr infusion schedule. Proc Am Soc Clin Oncol 14:479, 1995
9. Brodfuehrer J, Whitfield LR, Kowal C, Grove W, Bullen W, Waterhouse D, Natale R: Pharmacologically guided dose escalation in Phase I clinical trial of CI-980. Proc Am Assoc Cancer Res 33:529, 1992
10. Natale R, Waterhouse D, Grove W, Whitfield LR, Brodfuehrer J, Kowal C: Phase I clinical and pharmacokinetic trial of CI-980, a novel mitotic inhibitor. Proc Annu Meet Am Soc Clin Oncol 11:118, 1992
11. Rowinsky EK, Noe DA, Grochow LB, Bowling MK, Sartorious SE, O'Reilly S, Chen T-L, Donehower RC: Phase I and pharmacological study of CI-980, a synthetic and structurally unique antimicrotubule agent, on a 72-hour continuous infusion schedule in adults with solid tumors. Proc Am Soc Clin Oncol 14:459, 1995
12. Pazdur R, Diaz-Canton E, Meyers C, Abbruzzese J, Patt Y, Rivera E, Touroutoglou N, Edwards K, Bready B, Ajani JE: Phase II trial of CI-980 in metastatic colorectal carcinoma patients. Proc Am Assoc Clin Oncol 14:208, 1995
13. Verschraegen CF, Kudelka AP, Edwards CL, Meyers CA, Conrad CA, Freedman RS, Gonzalez de Leon C, Finnegan MB, Hord M, Mante R, Calayag M, Grove W: Phase II trial of CI-980 in advanced epithelial ovarian carcinoma. Proc Am Assoc Clin Oncol 14:271, 1995
14. Temple C Jr, Rener GA: Antimitotic agents: chiral isomers of ethyl 5-amino-1,2-dihydro-3-(4-hydroxyphenyl)-2-methylpyrido[3,4-b]pyrazin-7- ylcarbamate. J Med Chem 35: 988-993, 1992
15. Waud WR, Bowdon BJ, Temple CG Jr, Harrison SD Jr, Griswold DP Jr: Comparative antitumor activity and mechanistic studies of the S- and R-enantiomers of a novel 1,2-dihydropyrido-[3,4-b]pyrazine. Proc Am Assoc Cancer Res 30:565, 1989
16. De Ines C, Leynadier D, Barasoain I, Peyrot V, Garcia P, Briand C, Rener GA, Temple C Jr: Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dihydropteridine antitumor drug, CI-980, and its chiral isomer, NSC 613863. Cancer Res 54:75-84, 1994
17. Fry DW, Besserer JA, Boritzki TJ: Transport of the antitumor antibiotic CI-980 into L1210 leukemia cells by the reduced folate carrier system. Cancer Res 44:3366-3370, 1984
18. Fry DW, Besserer JA: Characterization of trimetrexate transport in human lymphoblastoid cells and development of impaired influx as a mechanism of resistance to lipophilic antifolates. Cancer Res 48:6986-6991, 1988
19. Goldman ID: The characteristics of the membrane transport of amethopterin and the naturally occurring folates. Ann NY Acad Sci 186:400-422, 1971
20. Plagemann PGW, Wohlhueter RM: Permeation of nucleosides, nucleic acid bases, and nucleotides in animal cells. Curr Topics Membranes Transport 14:225-330, 1980
21. Kelley EE, Modest EJ, Burns CP: Unidirectional membrane uptake of the ether lipid antineoplastic agent edelfosine by L1210 cells. Biochem Pharmacol 45:2435-2439, 1993
22. Vasanhakumar G, Ahmed NK: Comparative uptake, retention and cytotoxicity of daunorubicin by human myeloid cells. Biochem Pharmacol 35:1185-1190, 1986
23. Kamen BA, Eibl B, Cashmore A, Bertino J: Uptake and efficacy of trimetrexate (TMQ, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline), a non-classical antifolate in methotrexate-resistant leukemia cells in vitro. Biochem Pharmacol 33:1697-1699, 1984
24. Spinella MJ, Brigle KE, Sierra EE, Goldman ID: Distinguishing between folate receptor-α-mediated transport and reduced folate carrier-mediated transport in L1210 leukemia cells. J Biol Chem 270:7842-7849, 1995
25. Kamen BA, Johnson CA, Wang M-T, Anderson RGW: Regulation of the cytoplasmic accumulation of 5-methyltetrahydrofolate in MA104 cells is independent of folate receptor regulation. J Clin Invest 84:1379-1386, 1989